Roche Diagnostics Middle East demonstrated ‘in vitro’ diagnostics (IVD) and how it adds value to disease management, treatment choices and cost at the ongoing Arab Health Congress in Dubai.

Illustrated via a Medical Value Room at the congress, Roche highlighted its dedicated and fundamental medical value contribution in the areas of oncology, cardiology, hepatitis C virus (HCV) and women’s health (in particular pre-eclampsia).

The room was also open to medical professionals who wish to learn more about the important medical value that Roche Diagnostics makes towards disease management.

Michael Heuer, president, Europe, Middle East, Africa and Latin America diagnostics, said: “Through its numerous innovations in IVD testing technologies, Roche Diagnostics is at the forefront of personalised healthcare, providing highly accurate testing solutions that enable clinicians to rapidly stratify risk, leading to faster and more pertinent treatment decisions.”

“Our diagnostic solutions provide answers that improve patients’ lives and benefit society and the healthcare system in the Middle East,” added Moritz Hartmann, general manager of Roche Diagnostics Middle East.

Diagnostic solutions include the Roche cobas cTnT-hs test, which offers a high diagnostic accuracy for acute myocardial infarction (AMI), a major cause of death and disability worldwide; Elecsys sFlt-1 and PIGF for pre-eclampsia diagnosis and other types of hypertensive disorders; and the cobas EGFR test, help determine whether patients with non-small-cell lung carcinoma (NSMLC) carry epidermal growth factor receptor (EGFR) mutations.

The portfolio also includes the new state of the art diagnostic test Elecsys Anti-HCV II, which offers impoved accuracy in diagnosis, as well as additional tests that enable clinicians to monitor patients throughout the course of the disease. - TradeArabia News Service